The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase whose activity contributes to leukemia proliferation and survival. Compounds targeting the mTOR active site inhibit ...
Sirolimus oral solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in certain patients. Ozempic has been approved to reduce the risk of worsening ...
The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...
2010;67(24):2095-2106. Temsirolimus is primarily metabolized by the cytochrome P-450 (CYP) 3A4 isoenzyme to five major metabolites, with sirolimus being the principal active metabolite.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback